SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 📊Experiments 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / General: c9orf72-als-ftd-phenotype-mechanism

general 972 words KG: C9orf72

Contents

c9orf72-als-ftd-phenotype-mechanism

Knowledge Graph

Related Hypotheses (22)

Targeted Butyrate Supplementation for Microglial Phenotype M
Score: 0.56 PARP1 Inhibition Therapy
Score: 0.58 Heat Shock Protein 70 Disaggregase Amplification
Score: 0.51 Senescence-Associated Myelin Lipid Remodeling
Score: 0.51 Vocal Cord Neuroplasticity Stimulation
Score: 0.50

Autophagosome Maturation Checkpoint Control
Score: 0.49 Stress Granule Phase Separation Modulators
Score: 0.49 Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Tar
Score: 0.48 Circadian-Gated Maresin Biosynthesis Amplification
Score: 0.47 Arginine Methylation Enhancement Therapy
Score: 0.46 Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46 Cryptic Exon Silencing Restoration
Score: 0.46 Cross-Seeding Prevention Strategy
Score: 0.45 Lysosomal Membrane Repair Enhancement
Score: 0.45 Axonal RNA Transport Reconstitution
Score: 0.45 Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.43 Glycine-Rich Domain Competitive Inhibition
Score: 0.43 R-Loop Resolution Enhancement Therapy
Score: 0.43 Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.42 Serine/Arginine-Rich Protein Kinase Modulation
Score: 0.42 Low Complexity Domain Cross-Linking Inhibition
Score: 0.42 Nucleolar Stress Response Normalization
Score: 0.38

Related Analyses (25)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed

How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed What determines the specificity of TDP-43-induced mitochondr
neurodegeneration · failed How does chronic cGAS/STING activation downstream of TDP-43
neuroinflammation · failed What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed What mechanisms underlie neuronal resistance to autophagy in
neurodegeneration · failed What upstream mechanisms cause TDP-43 to trigger mPTP openin
neurodegeneration · failed What are the neuron-specific effects of ALS-causing mutation
neurodegeneration · failed How do non-cell autonomous effects of autophagy dysfunction
neurodegeneration · completed What are the molecular signatures that distinguish protectiv
neurodegeneration · failed RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived Synaptic pruning by microglia in early AD
neurodegeneration · archived TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived

Related Experiments (25)

s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40 Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40 Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40 C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40 Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40

FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40 Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40 Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40 ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40 ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40 Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40 Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40 Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40 Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40 Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40 FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40 Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40 N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40 Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40 Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40 Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40 PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40 Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40 TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40 Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40

See Also (11)

Ubiquitin
protein · KG edge: co_discussed TDP-43 Protein
redirect · KG edge: regulates CREB-independent Neuronal Survival Pathways
mechanism · KG edge: co_discussed Aging vs Neurodegeneration: Mechanistic Comparison Matr
mechanism · KG edge: co_discussed Actin Cytoskeleton Dynamics in Neurodegeneration
mechanism · KG edge: co_discussed

Packard Center for ALS Research
institution · KG edge: activates WDR41 Gene
gene · KG edge: interacts_with MMP9 Gene
gene · KG edge: regulates ACTB Gene
gene · KG edge: activates ABCA7 (Redirect)
redirect · KG edge: associated_with Frontotemporal Dementia (FTD)
disease · KG edge: associated_with

Knowledge Graph (12 edges)

C9orf72 co_discussed neuroinflammation

C9orf72 co_discussed TBK1

C9orf72 co_discussed VCP

C9orf72 activates ALS

C9orf72 interacts_with ALS

C9orf72 regulates MMP9

C9orf72 causes Frontotemporal dementia

C9orf72 causes lysosomal dysfunction

C9orf72 regulates TDP-43

C9orf72 interacts_with WDR41

SciDEX — scidex.ai — Dashboard | Atlas